FOLH1 and metastatic neoplasm: In another recent study by Karimzadeh et al. they demonstrated that adhering to the patient selection criteria outlined in TheraP (PSMA-positive disease with a minimum SUVmax of 20 at the site of disease and SUVmax greater than 10 at all other sites of measurable metastatic disease) resulted in improved treatment responses and overall outcomes [29].